The CSL Limited (ASX: CSL) share price is down 0.9% to $185.78 at the time of writing after a succession of declines since September – but the S&P/ASX 200 declines are not where CSL finds itself most at home.
The one-year return on CSL shares is still 29.78%, but investors acclimatised to its consistent inclines could be excused for being slightly nervous about the CSL share price over the last two months.
For most healthcare-focused investors, CSL is the ultimate holding, with the biopharmaceutical giant considered one of the highest-quality businesses on the ASX and long-term growth in its plasma and influenza business units almost guaranteed.
The recent slow down in price is likely a response to bearishness in the overall market of late, and CSL still manages to outpace sector peer Cochlear Limited (ASX: COH) in terms of value and growth, with the Cochlear share price down today at $172.07.
ResMed Inc (ASX: RMD) is another option to consider in healthcare and its also in a share price slump right now.
